ArticleBMC cancer2026
High-risk subgroup and associated genes identified by next generation sequencing in diffuse large B cell lymphoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiffuse large B cell lymphoma (DLBCL) displays genetic and clinical heterogeneity that limits the predictive value of cell-of-origin and LymphGen. We evaluated whether diagnostic targeted next generation sequencing (NGS) could predict outcomes and delineate high-risk subsets in routine practice. EXPERIMENTAL
designWe retrospectively analyzed tumors from 106 patients. Variants with allele frequency(VAF) ≥ 10% from a lymphoma-focused panel were curated into a binary mutation matrix. Random Forest regression identified genes associated with overall survival (OS) and progression-free survival (PFS). Principal-component analysis with k-means clustering stratified tumors, and groups were compared for survival, clinical and pathologic features, and LymphGen composition.
resultsThirty genes with strong prognostic signals were recovered, spanning canonical drivers and novel candidates. Clustering of these features yielded two molecular subgroups, one highly enriched for LymphGen-unclassified tumors. This subgroup showed significantly inferior PFS and a higher prevalence of adverse clinical factors like advanced IPI, stage, elevated LDH.
conclusionsTargeted NGS combined with machine learning and unsupervised clustering provides robust, clinical significant stratification in DLBCL, revealing a high-risk subgroup not captured by existing classification. These findings support incorporating panel-based sequencing into routine diagnostics to refine risk-adapted treatment and prioritize patients for intensified or novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.